Publications by authors named "Matthew Sheetz"

Claim this Profile
T
Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.
Matthew Sheetz, Philip Barrington, Sophie Callies, Paul H Berg, Juliet McColm

Br J Clin Pharmacol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-TGF-1 Antibody Therapy in Patients with Diabetic Nephropathy.
James Voelker, Paul H Berg, Matthew Sheetz, Kevin Duffin, Tong Shen

J Am Soc Nephrol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies.
Matthew J Sheetz, Lloyd Paul Aiello, Matthew D Davis, Ronald Danis, Toke Bek

Invest Ophthalmol Vis Sci· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2.
Lloyd Paul Aiello, Louis Vignati, Matthew J Sheetz, Xin Zhi, Aniz Girach

Retina· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2).
Matthew J Sheetz, Lloyd Paul Aiello, Nazila Shahri, Matthew D Davis, Keri A Kles

Retina· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruboxistaurin: PKC-beta inhibition for complications of diabetes.
Ronald P Danis, Matthew J Sheetz

Expert Opin Pharmacother· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus.
Nehal N Mehta, Matthew Sheetz, Karen Price, Lynn Comiskey, Shirish Amrutia

Cardiovasc Drugs Ther· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
Matthew D Davis, Matthew J Sheetz, Lloyd P Aiello, Roy C Milton, Ronald P Danis

Invest Ophthalmol Vis Sci· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.

Ophthalmology· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients.
Lloyd Paul Aiello, Allen Clermont, Vipin Arora, Matthew D Davis, Matthew J Sheetz

Invest Ophthalmol Vis Sci· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular understanding of hyperglycemia's adverse effects for diabetic complications.
Matthew J Sheetz, George L King

JAMA· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis